Myeloproliferative Neoplasms

>

Latest News

Image of bone marrow cells
As-Expected Ruxolitinib Starting Dose Outperforms Lower Dosage in Myelofibrosis

April 25th 2025

Both those receiving either expected or less-than-expected starting dosages of ruxolitinib for myelofibrosis treatment reduced daily dosages over 12 months.

Image of red blood cells
Rusfertide Plus SOC Reaches Response End Point in Phlebotomy-Dependent PV

March 9th 2025

light blue background with an outline of blood cells
Ropeginterferon Alfa-2b Effective in Phase 3 Essential Thrombocythemia Trial

January 9th 2025

blood cancer
Selinexor With Ruxolitinib Appears Safe, Effective in Myelofibrosis

December 13th 2024

Disease Progression May Be More Common in Lower-Risk Myelofibrosis
Disease Progression May Be More Common in Lower-Risk Myelofibrosis

June 17th 2024

Video Interviews

More News